Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin
- 24 January 2020
- journal article
- letter
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 55 (5), 1901903
- https://doi.org/10.1183/13993003.01903-2019
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug MonitoringTherapeutic Drug Monitoring, 2018
- First principles electronic and elastic properties of fresnoite Ba2TiSi2O8Materials Research Express, 2017
- Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic studyJournal of Antimicrobial Chemotherapy, 2017
- Membrane Filtration Is Suitable for Reliable Elimination of Mycobacterium tuberculosis from Saliva for Therapeutic Drug MonitoringJournal of Clinical Microbiology, 2017
- Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.European Respiratory Journal, 2017
- Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnosticsEuropean Respiratory Journal, 2016
- Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?European Respiratory Journal, 2013
- Clinical Validation of the Analysis of Linezolid and Clarithromycin in Oral Fluid of Patients with Multidrug-Resistant TuberculosisAntimicrobial Agents and Chemotherapy, 2013
- Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experienceEuropean Respiratory Journal, 2011
- Determination of Moxifloxacin in Human Plasma, Plasma Ultrafiltrate, and Cerebrospinal Fluid by a Rapid and Simple Liquid Chromatography-Tandem Mass Spectrometry MethodJournal of Analytical Toxicology, 2010